HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coty sales

This article was originally published in The Rose Sheet

Executive Summary

Net sales advanced 23 percent to a record $4 billion for the fiscal year ended June 30, 2008, the beauty company announces Sept. 12. The marketer of fragrance brands including Calvin Klein and Marc Jacobs attributed the success to its "talent in identifying and interpreting the latest consumer trends." The Coty Prestige division achieved revenues of $2.1 billion for the year, representing growth of 16 percent, with a strong global performance of the Daisy Marc Jacobs scent and sales of fragrances under the Chloe, Vera Wang and Davidoff brands, among others. The Coty Beauty business experienced sales growth of 33 percent to $1.9 billion, driven primarily by new launches including Kate by Kate Moss, as well as the purchase of Del Labs late last year (1"The Rose Sheet" Dec. 17, 2007, p. 5). In the coming year, Coty will focus its business on creating a "sizeable" skin care business, leveraging global scale and investing in organizational capabilities

You may also be interested in...



Newly Acquired Sally Hansen Marketer Is A “Natural Extension,” Coty Says

Del Labs' "well regarded" portfolio of North American beauty brands complements Coty's existing stable of brands and global distribution, Coty CEO Bernd Beetz says in a release announcing the firm's purchase of Del Labs' parent company, DLI Holding Corporation

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

UsernamePublicRestriction

Register

RS015670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel